Latest Johnson & Johnson News & Updates

See the latest news and media coverage for J&J. We track all announcements, press releases, and industry mentions in real time, all in one place.

Johnson & Johnson (J&J)

Global healthcare company developing medicines and medical technologies

jnj.com

Headquarters: New Brunswick, United States
Company type: Public company
Number of employees: 100,000+
Industry: Pharmaceuticals

Last updated Today

Latest news about Johnson & Johnson (J&J)

In short: J&J reported strong Q2 2026 growth, secured FDA approval for its OTTAVA surgical robot, and proposed a $5.5 billion talc settlement.

Company announcements

September 11 J&J

J&J presents new RYBREVANT lung cancer data at WCLC

Johnson & Johnson shares final overall survival and safety findings for its EGFR-mutated NSCLC therapies.

August 24 J&J

J&J announces FDA approval of IMAAVY for wAIHA

IMAAVY is the first treatment for this rare disease, showing durable hemoglobin responses and fatigue improvement in clinical trials.

August 17 J&J

Johnson & Johnson announces MONARCH QUEST 3 software update

The FDA-cleared update enhances AI-powered planning, navigation accuracy, and imaging compatibility for the robotically-assisted bronchoscopy platform.

August 4 J&J

J&J announces Jennifer Taubert's retirement and Tom Cavanaugh's appointment

Taubert led Innovative Medicine to over $60 billion in annual revenue during her 21-year tenure. Cavanaugh succeeds her and joins the Executive Committee on September 1, 2026.

Media coverage

Yesterday PMLiVE

J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE

Johnson & Johnson (J&J) has announced that the National Institute for Health and Care Excellence (NICE) has published Final ...

Yesterday Seeking Alpha

J&J reports phase 2b data on less-frequent lung cancer treatment

Johnson & Johnson's COPERNICUS Phase 2b results suggest less-frequent dosing may improve EGFR NSCLC care with low side effects.

Yesterday Marketscreener

Johnson & Johnson Announces New Results From Phase 2b COPERNICUS Study Evaluating RYBREVANT FASPRO Plus LAZCLUZE With Prophylactic Strategies

Johnson & Johnson announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib), with less...

September 14 MSN

Contineum, J&J's depression drug fails to meet mid-stage trial goal

Sept 15 (Reuters) - Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal...

Never miss news about J&J

Track J&J and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

J&J competitors & trending companies

Browse news for competitors to J&J and other trending companies.